Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Paul, and Stephen Walt concede that traditional balancing is not occurring, but argue nevertheless that rivals to the US are engaging in 'soft balancing.'More recent scholarly work has engaged the debate on soft balancing. Kai He suggested a new analytical framework, a negative balancing model, to explain why states do not form alliances or conduct arms races to balance against power or threats as they may have done in the past. He describes negative balancing as any strategy or diplomatic efforts aimed to undermine a rival's power. In contrast, positive balancing is actions or policies designed to strengthen a state's own power in world politics.
==== List of regions ==== Sometimes, overlaps and transition areas happen between the various regions of Lower Saxony. Several of the regions listed here are part of other, larger regions, that are also included in the list.
Sub-slab depressurization (soil suction) by increasing under-floor ventilation; Improving the ventilation of the house and avoiding the transport of radon from the basement into living rooms; Installing a radon sump system in the basement; Installing a positive pressurization or positive supply ventilation system. According to the EPA, the method to reduce radon "...primarily used is a vent pipe system and fan, which pulls radon from beneath the house and vents it to the outside", which is also called sub-slab depressurization, active soil depressurization, or soil suction. Generally indoor radon can be mitigated by sub-slab depressurization and exhausting such radon-laden air to the outdoors, away from windows and other building openings. "[The] EPA generally recommends methods which prevent the entry of radon. Soil suction, for example, prevents radon from entering your home by drawing the radon from below the home and venting it through a pipe, or pipes, to the air above the home where it is quickly diluted" and the "EPA does not recommend the use of sealing alone to reduce radon because, by itself, sealing has not been shown to lower radon levels significantly or consistently". Positive-pressure ventilation systems can be combined with a heat exchanger to recover energy in the process of exchanging air with the outside, and simply exhausting basement air to the outside is not necessarily a viable solution as this can actually draw radon gas into a dwelling.
== Clinical significance == Immunohistochemistry analysis of human myocytes has shown greater immunoreactivity of Ucn2 in myocytes of the failing heart compared to those of the healthy heart. This is a result of an innate mechanism in which Ucn2 acts to improve function of the failing heart. The pathophysiology of heart failure is often a consequence of improper calcium handling and relaxation resulting in a lower cardiac output, decreased blood flow and overall decreased heart function. Infusion of Ucn2 in healthy humans has shown a dose dependent increase in cardiac output, heart rate and left ventricle ejection fraction and a decrease in systemic vascular resistance. Ucn2 has been studied as potential treatment for individuals with heart failure.
Sources: en.wikipedia.org
=== Rashtriya Janata Party and Chief Minister === He floated his own party, named Rashtriya Janata Party and became Chief Minister with Congress Party's support in October 1996. He won by-poll to Gujarat Assembly from Radhanpur seat in early 1997. But he had to resign as Chief Minister during ongoing political turmoil in Gujarat in October 1997, and his fellow-rebel ex-BJP MLA Dilip Parikh became CM with Vaghela's reluctant blessings. Even Parikh's government did not last long and fresh elections for Gujarat Vidhan Sabha had to be called in 1998. Vaghela did not contest these elections. He merged his new party with Congress. BJP came back to power with thumping majority in Gujarat in 1998 and Keshubhai Patel became CM again.
On September 28 Hanmi and Zentec Pharmaceuticals agreed that Zentec would market Hanmi's small molecule cancer drug candidate, HM95573; Zentec paid $80 million upfront, with $830 million in milestones, and royalties. On September 29, Hanmi and Roche's cancer subsidiary Genentech announced a deal for Hanmi's Phase I cancer drug candidate, HM95573, which targets the MAPK/ERK pathway; Roche agreed to pay $80 million upfront, and the deal included $830 million in milestones. In December 2016 the Sanofi deal was reduced in scope, with Hanmi receiving back rights to the once-weekly insulin and the combination GLP1-RA/insulin product, and agreeing to repay Sanofi $250 million of the $434 million upfront payment. On December 3, 2019, Rapt Therapeutics and Hanami Pharmaceutical announced collaboration to develop and commercialize FLX475 in Asia. FLX475 is an oral, small molecule CCR4 antagonist in development for the treatment of multiple cancers. In August 2020, chairman and founder of Hanmi Pharmaceutical Lim Sung-ki died of a chronic disease. He was 80. On May 15, 2023, Athenex, which was Hanmi's U.S. partner for its anticancer product, Oraxol, filed for Chapter 11 bankruptcy protection.
The district's arterial roads are laid out on a grid system of north–south and east–west, corresponding to the concession roads of the original township, laid out to facilitate the establishment of farming communities. Kingston Road and Danforth Avenue were laid out prior to surveying the township, and both run diagonally in a southwest–northeast direction across the south end of Scarborough. From north to south, the major east–west arterial roads are Steeles Avenue, Finch Avenue, Sheppard Avenue, Ellesmere Road, Lawrence Avenue, Eglinton Avenue and St. Clair Avenue. From west to east, the major north–south arterial roads are Victoria Park Avenue, Pharmacy Avenue, Warden Avenue, Birchmount Road, Kennedy Road, Midland Avenue, Brimley Road, McCowan Road, Bellamy Road North, Markham Road, Scarborough Golf Club Road, Neilson Road, Morningside Avenue, Meadowvale Road and Port Union Road. Kingston Road was formerly Ontario Highway 2, and was the main highway through the district until the building of Highway 401, which runs east–west across the district, with six to eight lanes in each direction. The short, minor freeway Highway 2A runs parallel to Lake Ontario in the eastern part of Scarborough.
July 1971: The association "Choisir la cause des femmes" is created — with philosopher Simone de Beauvoir and lawyer Gisèle Halimi — to demand the repeal of the 1920 law criminalizing abortion. January 3, 1972: Law on parentage. It opens the right for the mother to challenge, under certain conditions, the presumption of the husband's paternity. January 3, 1972: Law on the stay-at-home mother's allowance. April 24, 1972: Decree applying Article 4 of Law 67-1176 of December 28, 1967, on birth control and repealing Articles L. 648 and L. 649 of the Public Health Code. July 13, 1972: Law establishing the general status of military personnel; access to military careers is not subject to sex-based discrimination. August 16, 1972: Decree on the specific status of the corps of national police inspectors, in which women are allowed to apply. December 22, 1972: Law affirming the principle of equal pay between genders. January 2, 1973: Law on the Labor Code, which updates it and includes provisions on women's work. January 9, 1973: Law amending and supplementing the French Nationality Code and concerning certain provisions related to French nationality; it notably authorizes the transmission of nationality by the mother to her child, whether the child is "legitimate or illegitimate." March 23, 1973: Decree establishing the special status of female military corps.
=== Severity (staging) and progression (grading) === The most recent (2017) periodontal disease classification uses CAL as a major factor in assessing both Severity and Progression. Alongside other factors like radiographic bone loss and tooth loss. CAL correlates to severity (Staging) as follows.
Sources: en.wikipedia.org
Stagnation pressure is the pressure a fluid exerts when it is forced to stop moving. Consequently, although a fluid moving at higher speed will have a lower static pressure, it may have a higher stagnation pressure when forced to a standstill. Static pressure and stagnation pressure are related by:
office Chris Iijima (1969), legal scholar, folksinger Andrei Markovits (1969), professor of comparative politics at the University of Michigan Michel Rosenfeld (1969), constitutional law scholar Mark Rosenzweig (1969), professor of economics at Yale University Steven M. Cohen (1970), sociologist, director of Berman Jewish Policy Archive at NYU's Robert F. Wagner Graduate School of Public Service Sheldon Danziger (1970), political scientist at the University of Michigan Lennard J. Davis (1970), professor of English at the University of Illinois at Chicago, specialist in disability studies John D'Emilio (1970), professor of history and gender studies at the University of Illinois at Chicago; winner of the Bill Whitehead Award in 2013 Samuel Estreicher (1970), professor at the New York University School of Law Peter Grossman (1970), professor of economics at Butler University; columnist, The Indianapolis Star Robert A. Leonard (1970), forensic linguist at Hofstra University and former member of rock band Sha Na Na Michael P. Mezzatesta (1970), art historian, director of the Nasher Museum of Art 1987–2003 Paul Starr (1970), sociologist; co-founder of The American Prospect and winner of the 1984 Pulitzer Prize for General Nonfiction Paul Berman (1971), historian and social critic Philip Nord (1971), historian and professor at Princeton University Steven J.
The IUPAC Color Books are a collection of books produced by the International Union of Pure and Applied Chemistry (IUPAC), containing its complete list of definitions. Although the colors are not the formal names of these books, they are commonly referred to simply by color by chemists. The set consists of eight volumes: Green, Red, Blue, Purple, Orange, Silver, White, and Gold.
The company will use the proceeds to further the development of its proprietary adjuvants or immune agonists that carry in a single molecule the various determinants needed to stimulate both innate and adaptive immunities, causing synergistic effects on T cell immunity. In March 2010, Bio-Synthesis launched a new custom service, PenetraINS, whereby two different molecules are joined together via selective chemical coupling for the purpose of up or down regulating gene expression in mammalian organisms.
In the United States it was the best-selling medication between 1968 and 1982, selling more than 2 billion tablets in 1978 alone. In 2023, it was the 183rd most commonly prescribed medication in the United States, with more than 2 million prescriptions. In 1985 the patent expired, and there are more than 500 brands available on the market. It is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.